More than 100 stakeholders across the British bio-based sector, including businesses, investors, industry organisations and manufacturers, have written a letter to the UK government calling for better backing of biotech companies looking to scale, manufacture and commercialise products on home turf. 

Co-led by the UK Bio-based and Biodegradable Industries Association (BBIA) and the BioRevolution Coalition, this letter sets out to highlight that the UK risks losing the fruits of research originally conducted within the country’s borders. Stakeholders sent this letter during the London Life Sciences Week, which is taking place at various venues across the city from 16-20 November. 

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

This comes as Britain retains its positioning as a quality hub for early-stage R&D, but stumbles in reaping the rewards of such efforts due to a challenging funding and commercial landscape. Previously, Ros Deegan, CEO of UK biotech OMass Therapeutics, told Pharmaceutical Technology that this primarily comes down to the transfer of high-quality science out of the country in the latter stages of clinical development, with companies often opting to seek refuge in more capital-rich locations like the US. 

While the UK’s bioeconomy already contributes around £325bn ($437bn) in gross value – the fourth largest in Europe – the nation ranks within the bottom 25% of all European countries when it comes to bioeconomy growth. 

However, with sufficient support and policy reform from the UK government, the BBIA estimates that the sector’s annual contribution could balloon to £500bn by 2030. 

With this goal in mind, the BBIA and the BioRevolution Coalition are calling on the British government to make the UK a more attractive location to scale and manufacture drugs and other bio-based products. To achieve this, they point to the need for the rapid deployment of the recent Engineering Biology Infrastructure Programme, as well as more targeted support for novel UK biomanufacturing plants. 

The authors also say that the government should focus on establishing clear ministerial leadership for the bioeconomy, while focusing on using its purchasing power to create early demand for bio-based products. 

According to Jen Vanderhoven, CEO of the BBIA and founder of the BioRevolution Coalition, Britain has already invested in the science, but the nation’s role is now to bring manufacturing onto home soil. 

“Too often, the technologies we invent and develop here are being scaled and manufactured overseas,” Vanderhoven commented, adding that the government needs to match the sector’s ambition with investments in scaling, policy evolution, and clear leadership to guide the next phase of the bio segment’s growth. 

“Our message is simple: Seed in Britain. Scale in Britain. Stay in Britain,” said Vanderhoven.